论文部分内容阅读
基于在两项分别名为VIEW 1和VIEW 2的Ⅲ期临床研究中获得阳性结果,Regeneron制药公司与其合作伙伴拜耳(Bayer)制药公司在欧盟递交了将抗血管内皮细胞生长因子(VEGF)重组蛋白VEGFTrap-Eye用于治疗湿性老年性黄斑变性(AMD)患
Based on positive results from two Phase III clinical studies titled VIEW 1 and VIEW 2 respectively, Regeneron Pharmaceuticals and its partner Bayer Pharmaceuticals filed in the European Union (EU) for the combination of anti-vascular endothelial growth factor (VEGF) recombinant protein VEGFTrap-Eye is used to treat patients with wet age-related macular degeneration (AMD)